Search Results
61 results
Your search is now limited to «Leukemia» expert search.
Your search is now limited to only one Source. To return to results from all sources click here. 04/19/2019 04:40
Even moderate consumption of red and processed meat increases bowel cancer risk Processed and red meat hitheadlines this week as our research linked moderate consumption to an increased risk of developing bowel cancer. Our scientists in Oxford found that for every 10,000 people who ate 21g of red and processed meat a day, 40 were diagnosed with bowel cancer. Eating 76g of processed or red meat a day caused 8 extra bowel cancer cases. Follow this Twitter thread for more info. Causes of cancer may leave 'fingerprints' on DNA Scientists in Cambridge say they have catalogued the tell-tale damage that environmental triggers of cancer, like tobacco smoke, leave in cells' DNA. The team told the... 04/17/2019 06:04
(April 17, 2019) -- Only about one in four people diagnosed with acute myelogenous leukemia (AML) survive five years after the initial diagnosis. To improve that survival rate, researchers at UTSA and the University of Texas MD Anderson Cancer Center created an online atlas to identify and classify protein signatures present at AML diagnosis. The new protein classifications will help researchers and clinicians recommend better treatment and personalized medicine for patients suffering from this aggressive cancer, which occurs in the blood and bone marrow. The breakthrough research is publishedin the latest April issue of Nature Biomedical Engineering. Amina Qutub is an Associate... 04/03/2019 09:15
Bio-Path Holdings Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2019 Highlighting Important Cancer Gene, STAT3, Therapeutic Strategy in Pancreatic, Non-Small Cell Lung Cancers and Acute Myelogenous Leukemia - Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology companyHOUSTONleveraging-Apr3,its2019proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announced that data from pre- clinical studies supporting the potential of BP1003, a novel liposome-incorporated STAT3 oligodeoxynucleotide inhibitor, for the treatment of pancreatic cancer, non-small cell lung cancer (NSCLC) and... 04/01/2019 14:38
Initial results from the trial show 88% molecular complete response at one month with well-tolerated safety profile Management to Hold Conference Call on April 2, 2019 at 8:00am ET / 1:00pm BST LONDON, April 01, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced that Claire Roddie MB, PhD, FRCPath, honorary senior lecturer, Cancer Institute, University College London (UCL), presented today initial data from the ongoing Phase 1/2 ALLCAR19 trial of AUTO1 in adult acute lymphoblastic B cell leukemia (ALL) as a late-breaking poster presentation... 04/01/2019 09:18
TOKYO, April 1, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Kenji Yasukawa, Ph.D. "Astellas") today announced results from the Phase 3 ADMIRAL clinical trial comparing XOSPATA® (gilteritinib) to salvage chemotherapy in adult patients with relapsed or refractory (resistant to treatment) Acute Myeloid Leukemia (AML) with a FLT3 mutation. 03/31/2019 20:47
Holi, the springtime Festival of Colors with roots in India, celebrates the coming of the season, and the triumph of good over evil. People participating in the annual tradition stateside say it’s hard to not have a good time, as people get together to throw and smear colorful powder on one another, eat, and dance to upbeat music. Doing all that while supporting a good cause only adds to the fun vibes, according to revelers who attended Holi for LLS, a fundraiser held in Fremont Sunday supporting the Leukemia & Lymphoma Society. A little over 200 people showed up to grassy patch... 03/27/2019 05:12
CAMBRIDGE, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for TIBSOVO® (ivosidenib) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy. 03/26/2019 08:13
HOUSTON, March 26, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ('Moleculin' or the 'Company'), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced positive interim safety and efficacy data from two ongoing open label, single arm Phase 1/2 studies of Annamycin.

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications